Abstract Committee Review

It would be good to know where exactly the injections (were they ID or IM or both ?) were performed for each patient, because it seems difficult to imagine that they were conducted at multiple sites of the hemibody. Furthermore the LANSS is a not a measure of allodynia but a screening questionnaire for neuropathic pain including one item referring to allodynia. This should be corrected.

I can provide an explanation for the injection protocol:

All injections were performed on the affected side of the body. Each patient had their own procedure protocol, which included different areas of the body, including intradermal papular injections in the allodynic area on the face, intramuscular injections in trigger points of target muscles in the head, neck, limbs, and trunk using electromyographic and ultrasound guidance.

On the face, the injections were performed as follows:

On the affected side of the face, in the area of allodynia, intradermally papularly, 0.5-1 unit per point, the distance between the points is 10 mm, the number of points is 8-10, the total dose for this area was 5-10 units in different patients.